Published in Pediatr Infect Dis J on March 01, 2002
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother (2004) 2.08
Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother (2012) 1.62
In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob Agents Chemother (2004) 1.55
Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. Clin Microbiol Rev (2013) 1.44
Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol (2003) 1.39
Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol (2010) 1.22
Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother (2010) 1.18
[Keratomycosis: diagnosis and therapy]. Ophthalmologe (2009) 1.17
Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice. Antimicrob Agents Chemother (2003) 1.16
Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis (2003) 1.14
Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob Agents Chemother (2010) 1.08
Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum. Antimicrob Agents Chemother (2002) 1.01
In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp. Antimicrob Agents Chemother (2005) 1.00
Severe osteomyelitis caused by Myceliophthora thermophila after a pitchfork injury. Ann Clin Microbiol Antimicrob (2006) 0.96
Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol (2005) 0.93
Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J (2012) 0.90
Arthritis and osteomyelitis due to Aspergillus fumigatus: a 17 years old boy with chronic granulomatous disease. Ann Clin Microbiol Antimicrob (2003) 0.90
Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis (2007) 0.89
CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy (2014) 0.88
Hospital-acquired phaeohyphomycosis due to Exserohilum rostratum in a child with leukemia. Can J Infect Dis Med Microbiol (2007) 0.88
Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant (2009) 0.88
Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother (2012) 0.88
Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis (2013) 0.87
Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2004) 0.87
Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag (2006) 0.86
Voriconazole-induced photosensitivity. Clin Med Res (2008) 0.86
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective. Can J Infect Dis Med Microbiol (2015) 0.85
High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant (2012) 0.84
Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer (2003) 0.84
Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. Eur J Pediatr (2005) 0.83
Voriconazole associated torsades de pointes in two adult patients with haematological malignancies. Med Mycol Case Rep (2014) 0.82
Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab (2013) 0.79
Osteoarticular Infections Caused by Non-Aspergillus Filamentous Fungi in Adult and Pediatric Patients: A Systematic Review. Medicine (Baltimore) (2015) 0.79
Pediatric antifungal agents. Curr Opin Infect Dis (2009) 0.79
Pulmonary aspergillosis in a patient with chronic granulomatous disease: confirmation by polymerase chain reaction and serological tests, and successful treatment with voriconazole. Eur J Clin Microbiol Infect Dis (2003) 0.79
Antifungal agents for the treatment of systemic fungal infections in children. Paediatr Child Health (2010) 0.78
Emergent Complications in the Pediatric Hematopoietic Stem Cell Transplant Patient. Clin Pediatr Emerg Med (2011) 0.78
CNS-manifestation of aspergillosis in an extremely low-birth-weight infant. Eur J Pediatr (2006) 0.78
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs (2014) 0.77
Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections. Can J Hosp Pharm (2009) 0.77
Treatment and prophylaxis of invasive candidiasis. Semin Perinatol (2012) 0.76
Antifungal agents for the treatment of systemic fungal infections in children. Can J Infect Dis Med Microbiol (2010) 0.75
Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis. Antimicrob Agents Chemother (2004) 0.75
Current evidence of antifungal prophylaxis and therapy in pediatric patients. Pediatr Rep (2011) 0.75
Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis. Antimicrob Agents Chemother (2008) 0.75
Successful management of pulmonary hemorrhage and aspergillosis in a patient with acute myeloid leukemia (AML-M3). Respir Med Case Rep (2015) 0.75
Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis. Pediatr Infect Dis J (2017) 0.75
Granulocyte transfusions in the management of invasive fungal infections. Br J Haematol (2017) 0.75
Voriconazole-Induced Photosensitivity in Children: A Case Report and Literature Review. Glob Pediatr Health (2014) 0.75
Successful treatment of fungal osteomyelitis with voriconazole in a patient with chronic granulomatous disease. Iran J Pediatr (2010) 0.75
Successful Treatment of Candida parapsilosis Fungemia in Two Preterms with Voriconazole. Case Rep Pediatr (2015) 0.75
Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan. J Infect Chemother (2013) 0.75
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Pharmacogenet Genomics (2017) 0.75
Antifungal therapy in children: an update. Eur J Pediatr (2012) 0.75
PATRIC, the bacterial bioinformatics database and analysis resource. Nucleic Acids Res (2013) 7.63
Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med (2009) 5.27
Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature (2005) 5.11
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
PATRIC: the comprehensive bacterial bioinformatics resource with a focus on human pathogenic species. Infect Immun (2011) 4.57
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. Infect Immun (2003) 3.61
Combination antifungal therapy. Antimicrob Agents Chemother (2004) 3.49
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 2.97
Cryptococcosis. Infect Dis Clin North Am (2006) 2.82
Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J (2002) 2.81
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis (2003) 2.73
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol (2007) 2.60
Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. J Clin Oncol (2012) 2.59
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Hsp90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr Biol (2009) 2.50
Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol (2010) 2.47
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A (2009) 2.35
Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryot Cell (2006) 2.35
Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis (2008) 2.33
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci U S A (2002) 2.29
Adenylyl cyclase functions downstream of the Galpha protein Gpa1 and controls mating and pathogenicity of Cryptococcus neoformans. Eukaryot Cell (2002) 2.21
Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS (2004) 2.11
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother (2004) 2.08
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest (2013) 2.00
Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun (2003) 2.00
Calcineurin is essential for Candida albicans survival in serum and virulence. Eukaryot Cell (2003) 1.98
Disruption of a nonribosomal peptide synthetase in Aspergillus fumigatus eliminates gliotoxin production. Eukaryot Cell (2006) 1.92
Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol (2004) 1.87
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother (2008) 1.79
Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol (2007) 1.78
Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog (2009) 1.76
Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis (2003) 1.74
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2002) 1.72
Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother (2008) 1.69
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs (2004) 1.67
The global burden of selected occupational diseases and injury risks: Methodology and summary. Am J Ind Med (2005) 1.67
When primary antifungal therapy fails. Clin Infect Dis (2008) 1.67
Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans. J Clin Invest (2003) 1.66
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J (2010) 1.66
Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis (2007) 1.65
PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90. PLoS Pathog (2010) 1.63
Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis (2007) 1.63
Carbonic anhydrase and CO2 sensing during Cryptococcus neoformans growth, differentiation, and virulence. Curr Biol (2005) 1.62
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Outcome of lung transplantation in patients with mycetomas. Chest (2002) 1.59
A MAP kinase cascade composed of cell type specific and non-specific elements controls mating and differentiation of the fungal pathogen Cryptococcus neoformans. Mol Microbiol (2003) 1.55
Differential effects of inhibiting chitin and 1,3-{beta}-D-glucan synthesis in ras and calcineurin mutants of Aspergillus fumigatus. Antimicrob Agents Chemother (2008) 1.55
Mating-type-specific and nonspecific PAK kinases play shared and divergent roles in Cryptococcus neoformans. Eukaryot Cell (2002) 1.55
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother (2006) 1.55
Role of PLB1 in pulmonary inflammation and cryptococcal eicosanoid production. Infect Immun (2003) 1.55
Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemother (2007) 1.54
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis (2006) 1.54
Identification of Cryptococcus neoformans temperature-regulated genes with a genomic-DNA microarray. Eukaryot Cell (2004) 1.54
Iatrogenic fungal meningitis: tragedy repeated. Ann Intern Med (2012) 1.54
Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans. Infect Immun (2002) 1.54
Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun (2007) 1.52
Is it time to abandon the use of amphotericin B bladder irrigation? Clin Infect Dis (2005) 1.51
Metabolic adaptation in Cryptococcus neoformans during early murine pulmonary infection. Mol Microbiol (2008) 1.49
In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother (2004) 1.46
Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation (2005) 1.45
Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm (2009) 1.44
Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis (2008) 1.44
In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother (2004) 1.44
The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. Infect Immun (2004) 1.44
Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis (2007) 1.43
Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infect Immun (2006) 1.41
Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm (2012) 1.41
Gpr1, a putative G-protein-coupled receptor, regulates morphogenesis and hypha formation in the pathogenic fungus Candida albicans. Eukaryot Cell (2004) 1.40
Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol (2003) 1.39
Prevalence of mixed cryoglobulins in relation to CD4 cell count among patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2004) 1.39
The growing family of mitochondrial carriers in Arabidopsis. Trends Plant Sci (2004) 1.39
Calcineurin target CrzA regulates conidial germination, hyphal growth, and pathogenesis of Aspergillus fumigatus. Eukaryot Cell (2008) 1.37
First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One (2009) 1.34
Cryptococcus neoformans {alpha} strains preferentially disseminate to the central nervous system during coinfection. Infect Immun (2005) 1.33
Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect (2011) 1.31
Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun (2013) 1.31
The global burden due to occupational injury. Am J Ind Med (2005) 1.30
Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One (2012) 1.30
Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol (2003) 1.29
Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol (2007) 1.29
Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother (2003) 1.29
Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host. MBio (2011) 1.29
Value of an inhalational model of invasive aspergillosis. Med Mycol (2004) 1.29
Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet (2008) 1.25
The Cryptococcus neoformans catalase gene family and its role in antioxidant defense. Eukaryot Cell (2006) 1.24
Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investig Drugs (2003) 1.24
Safety of voriconazole and dose individualization. Clin Infect Dis (2003) 1.23
A Rickettsia genome overrun by mobile genetic elements provides insight into the acquisition of genes characteristic of an obligate intracellular lifestyle. J Bacteriol (2011) 1.23